BD (BDX, Financial), a leading medical device company, experienced a significant stock movement with a 5.02% drop in its share price, reaching $232.77. The trading volume was approximately 1.94 million shares, with a turnover rate of 0.67% and a price fluctuation of 2.83%.
Recent financial reports reveal BD achieved a revenue of $5.168 billion, a net profit of $303 million, and earnings per share of $1.05. The company's gross profit amounted to $2.235 billion, with a price-to-earnings ratio of 39.24. Among 19 institutions providing ratings, 84% recommended buying, while 16% suggested holding, with no sell recommendations.
Within the medical device industry, BD's stock decline contrasts with the overall sector's 0.75% drop. Notable gainers in the sector included Microbot Medical Inc., Bionano Genomics, Inc., and Nephros, Inc. Active stocks with high turnover were Sharps Technology Inc., Avinger, Inc., and Bionano Genomics, Inc. Stocks with significant price swings included Nexgel Inc C/Wts 27/12/2026 (To Pur Com), Microbot Medical Inc., and Bionano Genomics, Inc.
BD is a global leader in manufacturing and distributing medical and surgical products such as needles, syringes, and sharps disposal units. The company's operations include pre-filled devices, diagnostic instruments, and flow cytometry systems. Its medical segment contributes nearly half of its business, with BD Life Sciences and BD Interventional accounting for the rest. International sales make up 43% of its revenue.
